UMEC
Sponsors
GlaxoSmithKline
Conditions
AsthmaPulmonary Disease, Chronic Obstructive
Phase 1
Phase 2
Evaluation of Umeclidinium Bromide in Combination With Fluticasone Furoate in COPD Subjects With an Asthmatic Component
CompletedNCT02164539
Start: 2014-07-01End: 2015-07-18Updated: 2017-10-11
Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma
CompletedNCT03012061
Start: 2017-01-25End: 2018-05-30Updated: 2020-10-28
Phase 3
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT01957163
Start: 2013-10-01End: 2014-04-01Updated: 2017-11-09
Study to Compare the Addition of Umeclidinium Bromide (UMEC) to Fluticasone Furoate (FF)/Vilanterol (VI), With Placebo Plus FF/VI in Subjects With Chronic Obstructive Pulmonary Disease (COPD) -Study 2
CompletedNCT02119286
Start: 2013-10-31End: 2014-04-30Updated: 2017-03-23
Comparative Study of Fluticasone Furoate(FF)/Umeclidinium Bromide (UMEC)/ Vilanterol (VI) Closed Therapy Versus FF/VI Plus UMEC Open Therapy in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
CompletedNCT02729051
Start: 2016-06-29End: 2017-05-23Updated: 2019-07-15